

# Graham Cook

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7287523/graham-cook-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

59 papers	2,622 citations	27 h-index	51 g-index
67 ext. papers	2,919 ext. citations	8.7 avg, IF	4.43 L-index

#	Paper	IF	Citations
59	Non-redundant activity of GSK-3 $\beta$ and GSK-3 $\alpha$ in T cell-mediated tumor rejection. <i>IScience</i> , <b>2021</b> , 24, 102553.	5.1	0
58	Multi-scale simulations of the T cell receptor reveal its lipid interactions, dynamics and the arrangement of its cytoplasmic region. <i>PLoS Computational Biology</i> , <b>2021</b> , 17, e1009232	5	1
57	Tumour cell CD99 regulates transendothelial migration via CDC42 and actin remodelling. <i>Journal of Cell Science</i> , <b>2021</b> , 134,	5.3	1
56	Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered NK cell phenotype in glioblastoma. <i>Clinical and Experimental Immunology</i> , <b>2020</b> , 200, 33-44	6.2	27
55	Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza. <i>PLoS Pathogens</i> , <b>2020</b> , 16, e1008716	7.6	5
54	Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza <b>2020</b> , 16, e1008716		
53	Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza <b>2020</b> , 16, e1008716		
52	Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza <b>2020</b> , 16, e1008716		
51	Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza <b>2020</b> , 16, e1008716		
50	Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza <b>2020</b> , 16, e1008716		
49	Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza <b>2020</b> , 16, e1008716		
48	Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma. <i>Cancer Research</i> , <b>2019</b> , 79, 2684-2696	10.1	31
47	Blood Coagulation Factor X Exerts Differential Effects on Adenovirus Entry into Human Lymphocytes. <i>Viruses</i> , <b>2018</b> , 10,	6.2	2
46	$\beta$ Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 2048-2063	15.9	46
45	A homozygous STIM1 mutation impairs store-operated calcium entry and natural killer cell effector function without clinical immunodeficiency. <i>Journal of Allergy and Clinical Immunology</i> , <b>2016</b> , 137, 955-7.	11.5	28
44	Natural killer (NK) cell function in paroxysmal nocturnal hemoglobinuria: a deficiency of NK cells, but not an NK cell deficiency. <i>Blood</i> , <b>2015</b> , 125, 1351-2	2.2	5
43	Controlled infection with a therapeutic virus defines the activation kinetics of human natural killer cells in vivo. <i>Clinical and Experimental Immunology</i> , <b>2015</b> , 180, 98-107	6.2	17

42	Blocking oncogenic RAS enhances tumour cell surface MHC class I expression but does not alter susceptibility to cytotoxic lymphocytes. <i>Molecular Immunology</i> , <b>2014</b> , 58, 160-8	4.3	27
41	TLR dependent XBP-1 activation induces an autocrine loop in rheumatoid arthritis synoviocytes. <i>Journal of Autoimmunity</i> , <b>2014</b> , 50, 59-66	15.5	45
40	A1.52 TLR-Dependent XBP1 activation induces an autocrine loop in rheumatoid arthritis synovial fibroblasts. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, A22.1-A22	2.4	
39	Licensed human natural killer cells aid dendritic cell maturation via TNFSF14/LIGHT. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, E5688-96	11.5	42
38	CUB domain containing protein 1 (CDCP1) modulates adhesion and motility in colon cancer cells. <i>BMC Cancer</i> , <b>2014</b> , 14, 754	4.8	9
37	Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 1202-10	2.4	128
36	Th17 Cells Are Increased in the Bone Marrow but Not the Peripheral Blood in Multiple Myeloma and Demonstrate Defective Functionality and Aberrant Phenotypes. <i>Blood</i> , <b>2014</b> , 124, 3420-3420	2.2	
35	Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells. <i>International Journal of Cancer</i> , <b>2013</b> , 132, 2327-38	7.5	42
34	Altered natural killer cell subset homeostasis and defective chemotactic responses in paroxysmal nocturnal hemoglobinuria. <i>Blood</i> , <b>2013</b> , 122, 1887-90	2.2	5
33	Human tumour immune evasion via TGF- $\beta$ blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity. <i>PLoS ONE</i> , <b>2011</b> , 6, e22842	3.7	106
32	A human NK cell activation/inhibition threshold allows small changes in the target cell surface phenotype to dramatically alter susceptibility to NK cells. <i>Journal of Immunology</i> , <b>2011</b> , 186, 1538-45	5.3	43
31	Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trial. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 5312-9	12.9	35
30	Identification of the BCL2/adenovirus E1B-19K protein-interacting protein 2 (BNIP-2) as a granzyme B target during human natural killer cell-mediated killing. <i>Biochemical Journal</i> , <b>2010</b> , 431, 423-31	3.8	12
29	The NLRP3 inflammasome, a target for therapy in diverse disease states. <i>European Journal of Immunology</i> , <b>2010</b> , 40, 631-4	6.1	40
28	Detecting variable (V), diversity (D) and joining (J) gene segment recombination using a two-colour fluorescence system. <i>Mobile DNA</i> , <b>2010</b> , 1, 9	4.4	3
27	Papillon-Lefèvre syndrome and malignant melanoma. <i>Dermatology</i> , <b>2009</b> , 219, 187-8	4.4	5
26	Proteolytic activation of the cytotoxic phenotype during human NK cell development. <i>Journal of Immunology</i> , <b>2009</b> , 183, 803-13	5.3	16
25	Haematopoietic repopulating activity in human cord blood CD133+ quiescent cells. <i>Bone Marrow Transplantation</i> , <b>2009</b> , 43, 627-35	4.4	17

24	High-risk human papillomavirus E7 expression reduces cell-surface MHC class I molecules and increases susceptibility to natural killer cells. <i>Oncogene</i> , <b>2008</b> , 27, 1794-9	9.2	48
23	Cancer and the immune system: an overview. <i>Oncogene</i> , <b>2008</b> , 27, 5868	9.2	14
22	Primer: inflammasomes and interleukin 1beta in inflammatory disorders. <i>Nature Clinical Practice Rheumatology</i> , <b>2008</b> , 4, 34-42		230
21	Profiling killers; unravelling the pathways of human natural killer cell function. <i>Briefings in Functional Genomics &amp; Proteomics</i> , <b>2008</b> , 7, 8-16		3
20	The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. <i>Cancer Research</i> , <b>2007</b> , 67, 8444-9	10.1	243
19	Expression of the CUB domain containing protein 1 (CDCP1) gene in colorectal tumour cells. <i>FEBS Letters</i> , <b>2007</b> , 581, 1137-42	3.8	30
18	A flow cytometric assay for analysis of natural-killer cell-mediated cytolysis of adenovirus-transformed cells. <i>Methods in Molecular Medicine</i> , <b>2007</b> , 131, 221-30		5
17	A family with Papillon-Lefevre syndrome reveals a requirement for cathepsin C in granzyme B activation and NK cell cytolytic activity. <i>Blood</i> , <b>2006</b> , 107, 3665-8	2.2	65
16	Differential expression of LFA-3, Fas and MHC Class I on Ad5- and Ad12-transformed human cells and their susceptibility to lymphokine-activated killer (LAK) cells. <i>Virology</i> , <b>2005</b> , 338, 297-308	3.6	6
15	Lymphodepletion in the ApcMin/+ mouse model of intestinal tumorigenesis. <i>Blood</i> , <b>2004</b> , 103, 1050-8	2.2	51
14	Antibody repertoires of four- and five-feature translocus mice carrying human immunoglobulin heavy chain and kappa and lambda light chain yeast artificial chromosomes. <i>Journal of Immunology</i> , <b>1999</b> , 163, 6898-906	5.3	43
13	MAFA-L, an ITIM-containing receptor encoded by the human NK cell gene complex and expressed by basophils and NK cells. <i>European Journal of Immunology</i> , <b>1998</b> , 28, 3755-62	6.1	53
12	High resolution restriction mapping of YACs using chromosome fragmentation. <i>Nucleic Acids Research</i> , <b>1996</b> , 24, 1585-6	20.1	4
11	A complete map of the human immunoglobulin VH locus. <i>Annals of the New York Academy of Sciences</i> , <b>1995</b> , 764, 43-6	6.5	23
10	Comparison of the human germline and rearranged VH repertoire reveals complementarity between germline variability and somatic mutation. <i>Annals of the New York Academy of Sciences</i> , <b>1995</b> , 764, 180-2	6.5	4
9	The human immunoglobulin VH repertoire. <i>Trends in Immunology</i> , <b>1995</b> , 16, 237-42		406
8	Organization of the human immunoglobulin lambda light-chain locus on chromosome 22q11.2. <i>Human Molecular Genetics</i> , <b>1995</b> , 4, 983-91	5.6	112
7	Human immunoglobulin VH and D segments on chromosomes 15q11.2 and 16p11.2. <i>Human Molecular Genetics</i> , <b>1994</b> , 3, 853-60	5.6	70

6	A map of the human immunoglobulin VH locus completed by analysis of the telomeric region of chromosome 14q. <i>Nature Genetics</i> , <b>1994</b> , 7, 162-8	36.3	229
5	HAPPY mapping of a YAC reveals alternative haplotypes in the human immunoglobulin VH locus. <i>Nucleic Acids Research</i> , <b>1993</b> , 21, 4524-9	20.1	33
4	A second B cell-specific enhancer 3' of the immunoglobulin heavy-chain locus. <i>Nature</i> , <b>1990</b> , 344, 165-8	50.4	203
3	Sexist ads. <i>Nature</i> , <b>1986</b> , 321, 106-106	50.4	1
2	CD99 regulates cancer cell transendothelial migration and endothelial cell function via CDC42 and actin remodelling		1
1	The CXCR6/CXCL16 axis links inflamm-aging to disease severity in COVID-19 patients		6